Cargando…
Bilirubin Nanoparticle Treatment in Obese Mice Inhibits Hepatic Ceramide Production and Remodels Liver Fat Content
Studies have indicated that increasing plasma bilirubin levels might be useful for preventing and treating hepatic lipid accumulation that occurs with metabolic diseases such as obesity and diabetes. We have previously demonstrated that mice with hyperbilirubinemia had significantly less lipid accum...
Autores principales: | Kipp, Zachary A., Martinez, Genesee J., Bates, Evelyn A., Maharramov, Agil B., Flight, Robert M., Moseley, Hunter N. B., Morris, Andrew J., Stec, David E., Hinds, Terry D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9965094/ https://www.ncbi.nlm.nih.gov/pubmed/36837834 http://dx.doi.org/10.3390/metabo13020215 |
Ejemplares similares
-
Suppressing Hepatic UGT1A1 Increases Plasma Bilirubin, Lowers Plasma Urobilin, Reorganizes Kinase Signaling Pathways and Lipid Species and Improves Fatty Liver Disease
por: Bates, Evelyn A., et al.
Publicado: (2023) -
Bilirubin Levels Are Negatively Correlated with Adiposity in Obese Men and Women, and Its Catabolized Product, Urobilin, Is Positively Associated with Insulin Resistance
por: Kipp, Zachary A., et al.
Publicado: (2023) -
Bilirubin Nanoparticles Reduce Diet-Induced Hepatic Steatosis, Improve Fat Utilization, and Increase Plasma β-Hydroxybutyrate
por: Hinds, Terry D., et al.
Publicado: (2020) -
Identification of Binding Regions of Bilirubin in the Ligand-Binding Pocket of the Peroxisome Proliferator-Activated Receptor-A (PPARalpha)
por: Gordon, Darren M., et al.
Publicado: (2021) -
Bilirubin, a new therapeutic for kidney transplant?
por: Sundararaghavan, Vikram L., et al.
Publicado: (2018)